8-K: BioMarin Prices $850M Notes, Secures $3.4B for Amicus Buy

BioMarin Pharmaceutical Inc. announced the pricing of $850 million in senior unsecured notes and completed syndication for $2 billion in term loans to finance its acquisition of Amicus Therapeutics.

Summary

• BioMarin Pharmaceutical Inc. priced an offering of $850 million of 5.500% senior unsecured notes due 2034.
• The offering is a private placement to qualified institutional buyers and non-U.S. persons, expected to close on February 12, 2026.
• The company completed syndication of a new $2 billion senior secured term loan B facility.
• This facility is in addition to an $800 million senior secured term loan A facility and a $600 million senior secured revolving credit facility, totaling $3.4 billion in new senior secured credit facilities.
• Net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will fund the acquisition of Amicus Therapeutics, Inc. and related expenses.
• Gross proceeds from the notes will be held in an escrow account, with a mandatory redemption if the acquisition is not completed by December 19, 2026.
• The notes will accrue interest at 5.500% annually, payable semiannually, and mature on February 15, 2034.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as BioMarin has successfully secured substantial financing for a strategic acquisition, demonstrating access to capital markets and progress on its growth strategy, despite the increase in debt.

Positives

• Successfully secured significant financing ($850 million in notes and $2 billion term loan B) for the pending acquisition of Amicus Therapeutics, Inc.
• The financing package, including term loans and a revolving credit facility, provides substantial capital for the acquisition and operational flexibility.
• The acquisition of Amicus Therapeutics, Inc. could expand BioMarin's product portfolio and market reach in rare diseases.

Negatives

• Incurrence of $850 million in new senior unsecured debt, increasing the company's overall leverage.
• The 5.500% interest rate on the notes represents a new interest expense burden.
• The notes are structurally subordinated to liabilities of non-guaranteeing subsidiaries and effectively subordinated to secured debt.

Risks

• The proposed notes offering, new senior secured credit facilities, and acquisition may not close as anticipated.
• There are risks and uncertainties regarding the timing to consummate these transactions.
• If the acquisition of Amicus Therapeutics is not completed by December 19, 2026, BioMarin will be required to redeem all of the notes, potentially incurring additional costs or liquidity challenges.
• The notes and related guarantees will be structurally subordinated to all liabilities of BioMarin's subsidiaries that do not guarantee the notes.
• The notes and related guarantees will be effectively subordinated to BioMarin's and the guarantors' existing and future secured indebtedness to the extent of the value of such applicable collateral.
• The indenture governing the notes contains customary covenants that restrict the ability of BioMarin and its subsidiaries to incur additional debt, pay dividends, make certain restricted payments, incur debt secured by liens, dispose of assets, or engage in consolidations and mergers.

Future Outlook

BioMarin expects the $850 million notes offering to close on or about February 12, 2026, and intends to use the proceeds, along with new term loan facilities and cash, to fund the pending acquisition of Amicus Therapeutics, Inc. The company also anticipates entering into a $600 million senior secured revolving credit facility in connection with the acquisition.

Industry Context

StockSavvy.ai notes that BioMarin's strategic financing moves align with a trend in the biotechnology sector where established rare disease companies leverage debt markets to fund significant acquisitions, aiming to expand their therapeutic portfolios and market share. This approach allows for growth without immediate equity dilution, common in a competitive M&A landscape for specialized biopharma assets.

Comparison to Industry Standards

• StockSavvy.ai observes that the 5.500% interest rate on BioMarin's senior unsecured notes is competitive for a company of its size and credit profile in the current market environment, especially for a private placement.
• The total debt financing package of $3.4 billion for the Amicus Therapeutics acquisition is substantial, comparable to recent large-scale M&A financing seen in the biotech sector, such as Pfizer's acquisition of Seagen or AbbVie's acquisition of Allergan, though on a smaller scale.
• The structure, including both unsecured notes and secured term loans, is a common strategy for optimizing capital costs and flexibility in large corporate transactions, similar to financing structures used by peers like Vertex Pharmaceuticals or Alexion Pharmaceuticals for their growth initiatives.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through the strategic acquisition of Amicus Therapeutics, but also increased leverage and interest expense.
• Creditors: New senior unsecured noteholders will rank equally with existing unsubordinated debt, but structurally and effectively subordinated to certain other liabilities.
• Employees: Potential for integration challenges and opportunities following the acquisition of Amicus Therapeutics.
• Customers/Patients: Expansion of BioMarin's rare disease portfolio through the acquisition could lead to new or enhanced treatment options.

Next Steps

• Closing of the $850 million senior unsecured notes offering on or about February 12, 2026.
• Consummation of the acquisition of Amicus Therapeutics, Inc.
• Entry into the $600 million senior secured revolving credit facility.
• First semiannual interest payment on the notes on August 15, 2026.

Key Dates

Recommendation

The successful securing of financing for the Amicus Therapeutics acquisition is a necessary step for BioMarin's strategic growth. While the acquisition itself could be a long-term positive, the immediate impact involves increased debt and associated interest expenses. The market has likely already factored in the acquisition announcement, and this financing update confirms the execution without introducing significant new upside or downside beyond the initial acquisition news. Investors should hold to observe the integration of Amicus and the financial performance post-acquisition.

Keywords

BioMarin Pharmaceutical, BMRN, Amicus Therapeutics, Acquisition, Senior Unsecured Notes, Debt Offering, Term Loan, Credit Facility, Biotechnology, Rare Disease, Financing, Mergers and Acquisitions